Clinical Trial: TcelnaTM (imilecleucel-T) - National Multiple Sclerosis Society

Skip to navigation Skip to content

Clinical Trial: TcelnaTM (imilecleucel-T)

Share

Details
Type of MS: SPMS
Treatment mode of action: To affect immune function
Number of Subjects: 180
Medication: TcelnaTM
Location: AZ|CA|FL|GA|IN|KS|KY|MA|NY|NC|OH|OR|PA|TX|VT|VA|WA
Contact Information
Maryann Murray
(281) 719-3405
mmurray@opexatherapeutics.com

Funding:

Opexa Therapeutics, Inc., of The Woodlands, Texas

Description

A phase 2 double-blind, placebo controlled multi-center study (also known as the Abili-T study) to evaluate the efficacy and safety of imilecleucel-T in people with secondary-progressive multiple sclerosis.

Share